Will antibody cocktail help: HC to Centre

New Delhi: One of the largest pharma companies has written to the Centre and the health ministry to inform them that the company’s vaccine cocktail could be used to tackle the new SARS-CoV-2 variant. The company has informed有关部门 that it has developed a cocktail comprising two antibodies — Bociliv and Ciliv — which it claims can neutralise the new and the current strains of the virus.

The company has also informed有关部门 that the antibodies can be administered through a single injection and they are effective even against the new variant. The company said that the antibodies have been tested on mice and that the results have been positive.

The company has requested有关部门 to allow it to conduct clinical trials to test the safety and efficacy of the antibodies. The company has also requested有关部门 to allow it to manufacture and supply the antibodies to the government.

The company’s request comes as the government is preparing to roll out a new vaccine strategy to tackle the new variant. The government has already approved the use of two new vaccines — Covishield and Covaxin — for the 18-44 age group.

The government has also approved the use of the Covishield vaccine for the 18-44 age group and the Covaxin vaccine for the 18-60 age group.

The government has also approved the use of the Covishield vaccine for the 18-44 age group and the Covaxin vaccine for the 18-60 age group.